Switch theme
Sign up to access all valuation multiples
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
2007
172
LTM Revenue $225M
Last FY EBITDA $48.1M
$131M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Puma Biotechnology has a last 12-month revenue (LTM) of $225M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Puma Biotechnology achieved revenue of $230M and an EBITDA of $48.1M.
Puma Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Puma Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $225M | XXX | $230M | XXX | XXX | XXX |
| Gross Profit | $163M | XXX | $166M | XXX | XXX | XXX |
| Gross Margin | 72% | XXX | 72% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $48.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 21% | XXX | XXX | XXX |
| EBIT | $31.8M | XXX | $31.0M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $26.0M | XXX | $30.3M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Puma Biotechnology's stock price is $3.
Puma Biotechnology has current market cap of $163M, and EV of $131M.
See Puma Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $131M | $163M | XXX | XXX | XXX | XXX | $0.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Puma Biotechnology has market cap of $163M and EV of $131M.
Puma Biotechnology's trades at 0.6x EV/Revenue multiple, and 2.7x EV/EBITDA.
Equity research analysts estimate Puma Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Puma Biotechnology has a P/E ratio of 6.3x.
See valuation multiples for Puma Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $163M | XXX | $163M | XXX | XXX | XXX |
| EV (current) | $131M | XXX | $131M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBIT | 4.1x | XXX | 4.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 6.3x | XXX | 5.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 3.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPuma Biotechnology's last 12 month revenue growth is -2%
Puma Biotechnology's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.8M for the same period.
Puma Biotechnology's rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Puma Biotechnology's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Puma Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 19% | XXX | 19% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Puma Biotechnology acquired XXX companies to date.
Last acquisition by Puma Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Puma Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Puma Biotechnology founded? | Puma Biotechnology was founded in 2007. |
| Where is Puma Biotechnology headquartered? | Puma Biotechnology is headquartered in United States of America. |
| How many employees does Puma Biotechnology have? | As of today, Puma Biotechnology has 172 employees. |
| Who is the CEO of Puma Biotechnology? | Puma Biotechnology's CEO is Mr. Alan H. Auerbach. |
| Is Puma Biotechnology publicy listed? | Yes, Puma Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Puma Biotechnology? | Puma Biotechnology trades under PBYI ticker. |
| When did Puma Biotechnology go public? | Puma Biotechnology went public in 2012. |
| Who are competitors of Puma Biotechnology? | Similar companies to Puma Biotechnology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Puma Biotechnology? | Puma Biotechnology's current market cap is $163M |
| What is the current revenue of Puma Biotechnology? | Puma Biotechnology's last 12 months revenue is $225M. |
| What is the current revenue growth of Puma Biotechnology? | Puma Biotechnology revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Puma Biotechnology? | Current revenue multiple of Puma Biotechnology is 0.6x. |
| Is Puma Biotechnology profitable? | Yes, Puma Biotechnology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
